Clinical Trials

A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

February 27th, 2024 | Clinical Trials

NCT Number: NCT06136650 Phase: PHASE3 Trial Summary: The purpose of this study is to assess the efficacy and safety of MK-5684 plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metast – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Merck Sharp & Dohme LLC Acronym:

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT05806814 Phase: PHASE1 Trial Summary: Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Oklahoma Acronym: OUSCCEXCITE

A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT04586270 Phase: PHASE1 Trial Summary: The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Taiho Oncology, Inc. Acronym:

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

February 27th, 2024 | Clinical Trials

NCT Number: NCT05806515 Phase: PHASE2 Trial Summary: This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): SWOG Cancer Research Network Acronym:

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT05946213 Phase: PHASE3 Trial Summary: This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology Acronym:

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

February 27th, 2024 | Clinical Trials

NCT Number: NCT06085664 Phase: PHASE1|PHASE2 Trial Summary: To learn about the safety and effects of a drug called REGN5678 when it is given to patients with high-risk prostate cancer. – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT06218667 Phase: PHASE1|PHASE2 Trial Summary: The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment t – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

February 27th, 2024 | Clinical Trials

NCT Number: NCT05708950 Phase: Phase 1|Phase 2 Trial Summary: The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors.… – see link above for mo – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Kineta Inc. Acronym:

High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients

February 27th, 2024 | Clinical Trials

NCT Number: NCT05838716 Phase: PHASE3 Trial Summary: This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation t – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Rochester NCORP Research Base Acronym:

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

February 27th, 2024 | Clinical Trials

NCT Number: NCT04777071 Phase: Phase 2 Trial Summary: This trial studies how well 68Ga-PSMA-11 PET/CT scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET/CT may find and diagnose prosta – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Washington Acronym:

Pin It on Pinterest